Skip to main content

Castle Biosciences

Castle Biosciences Inc is an American commercial-stage dermatologic diagnostics company focused on personalized clinical test solutions. The company develops and commercializes gene expression profiling diagnostic tests, including DecisionDx-Melanoma and DecisionDx-SCC, to guide treatment decisions in skin cancers and Barrett's esophagus. Main revenue drivers comprise diagnostic test billing fees paid by Medicare, commercial health insurers, and clinical healthcare providers. Castle Biosciences serves dermatologists, mohs surgeons, dermatopathologists, and gastroenterologists across the United States. The company holds a prominent position in precision gene expression profiling tests for dermatologic oncology. Headquartered in Friendswood, Texas, Castle Biosciences Inc is listed on the Nasdaq Stock Market.

3 of the funds FundTelligence covers report a position in Castle Biosciences.

Legal name
CASTLE BIOSCIENCES
Sector
Health Care
Country
United States
Funds holding it
3
Exposure themes
Cancer Profiling, Molecular Diagnostics, Precision Medicine & Genomics

Funds holding Castle Biosciences

Loading...